Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences ConferenceGlobeNewsWire • 03/08/21
Implied Volatility Surging for Cassava Sciences (SAVA) Stock OptionsZacks Investment Research • 02/26/21
Cassava Sciences jumps 16% on meeting with FDA paving the way for phase 3 study of Alzheimer's treatmentBusiness Insider • 02/22/21
Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer's DiseaseGlobeNewsWire • 02/22/21
Is Cassava Sciences (SAVA) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/18/21
Cassava Sciences Announces Closing of $200 Million Registered Direct OfferingGlobeNewsWire • 02/12/21
Cassava Sciences Seeks $200M From Equity Offering At 15% Discount To Fund Development Of Lead CandidateBenzinga • 02/10/21
Cassava Sciences to offer $200 million of shares priced at $49 each vs. $50.29 at Tuesday's closeMarket Watch • 02/10/21
Cassava Sciences Announces $200 Million Registered Direct Offering of Common StockGlobeNewsWire • 02/10/21